Product Overview: Furostat-250 (Cefuroxime Axetil 250 mg)
Furostat-250 Tablets, manufactured by Solvista Healthcare, is a high-potency antibiotic featuring Cefuroxime Axetil IP 250 mg. As an advanced second-generation cephalosporin, it serves as a critical tool in the modern medical arsenal against a wide range of bacterial infections. This detailed profile explores the clinical significance, indications, and quality standards of Furostat-250.
Chemical Composition and Classification
The active pharmaceutical ingredient (API) in Furostat-250 is Cefuroxime Axetil. It is an oral prodrug of Cefuroxime, a second-generation cephalosporin. Upon ingestion, the axetil moiety is hydrolyzed, releasing the active Cefuroxime into the bloodstream. Cefuroxime works by inhibiting bacterial cell wall synthesis, specifically targeting penicillin-binding proteins (PBPs), which leads to the eventual lysis and death of the bacteria.
Therapeutic Spectrum
Furostat-250 is recognized for its Broad-Spectrum Bacterial Coverage. Unlike first-generation cephalosporins, second-generation agents like Cefuroxime offer enhanced activity against Gram-negative pathogens while maintaining significant efficacy against Gram-positive bacteria.
Key Benefits Mentioned:
- Effective Against Gram-Positive & Gram-Negative Pathogens: It is highly effective against common clinical isolates such as Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
- Rapid Clinical Response: The pharmacokinetic profile allows for quick absorption, leading to a faster reduction in symptoms.
- High Patient Compliance: The 250 mg dosage form is designed for ease of administration, encouraging patients to complete their full course of treatment.
Clinical Indications
Furostat-250 is indicated for the treatment of several infectious conditions caused by susceptible strains of microorganisms:
- Respiratory Tract Infections: It is commonly prescribed for Upper Respiratory Tract Infections (URTI) like sinusitis, pharyngitis, and tonsillitis, as well as Lower Respiratory Tract Infections (LRTI) such as acute bronchitis and community-acquired pneumonia.
- Urinary Tract Infections (UTI): It effectively treats uncomplicated UTIs, including cystitis and pyelonephritis caused by susceptible bacteria.
- Skin and Soft Tissue Infections: Furostat-250 is used to manage infections like furunculosis, pyoderma, and impetigo.
- Other Susceptible Infections: It can also be utilized in the treatment of early Lyme disease and certain sexually transmitted infections like gonorrhea.
Quality Assurance and Manufacturing
Solvista Healthcare emphasizes rigorous quality standards in the production of Furostat-250. The product bears several prestigious certifications:
- WHO-GMP Certified: Manufactured under World Health Organization – Good Manufacturing Practices.
- ISO Certified: Adherence to International Organization for Standardization protocols ensures consistent safety and efficacy.
- Quality Assured: Multiple levels of testing are conducted to ensure that every tablet meets the “IP” (Indian Pharmacopoeia) standards.
